{"altmetric_id":194094,"counts":{"readers":{"mendeley":85,"citeulike":2,"connotea":1},"facebook":{"unique_users_count":2,"unique_users":["148109355242779","147792885286506"],"posts_count":2},"blogs":{"unique_users_count":1,"unique_users":[52566],"posts_count":1},"news":{"unique_users_count":1,"unique_users":["ctv_news"],"posts_count":1},"total":{"posts_count":19},"twitter":{"unique_users_count":11,"unique_users":["cells_nnm","pvo1reuma","srfcure","nicholasmmurphy","eriksjakobsons","transplant_doc","larhumato","rubenroa","srviswanathan","celltrials","sanguinebiomab"],"posts_count":15}},"selected_quotes":["Results of Ph II ASSIST trial: Autologous non-ablative haemopoietic stem-cell transplantation in systemic sclerosis (US)","Autotransplants improve skin and pulmonary function in patients with systemic sclerosis: preferable to pulse cytoxan","Autogreffe de moelle dans la sclerodermie : resultats impressionnants dans le Lancet cette semaine.","Autologous non-myeloablative HSCT vs. pulse cyclophosphamide for systemic sclerosis (ASSIST): Phase 2 trial :","referral by dr Farge on the work on #systemicsclerosis by Richart Burt and his 2011Lancet publication #EBMT17"],"citation":{"abstract":"Non-randomised studies of haemopoietic stem-cell transplantation (HSCT) in systemic sclerosis have shown improvements in lung function and skin flexibility but high treatment-related mortality. We aimed to assess safety and efficacy of autologous non-myeloablative HSCT in a phase 2 trial compared with the standard of care, cyclophosphamide.","abstract_source":"pubmed","altmetric_jid":"4f6fa6393cf058f610008b2a","authors":["Richard K Burt","Sanjiv J Shah","Karin Dill","Thomas Grant","Mihai Gheorghiade","James Schroeder","Robert Craig","Ikuo Hirano","Karin Marshall","Eric Ruderman","Borko Jovanovic","Francesca Milanetti","Sandeep Jain","Kristin Boyce","Amy Morgan","James Carr","Walter Barr"],"doi":"10.1016\/s0140-6736(11)60982-3","first_seen_on":"2011-07-21T18:14:11+00:00","issns":["0140-6736","01406736"],"issue":"9790","journal":"The Lancet","last_mentioned_on":1490603064,"links":["http:\/\/www.thelancet.com\/journals\/lancet\/article\/PIIS0140-6736(11)60982-3\/fulltext","http:\/\/www.thelancet.com\/journals\/lancet\/article\/PIIS0140-6736(11)60982-3\/abstract?rss=yes","http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/21777972?dopt=Abstract","http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/21777972","http:\/\/www.thelancet.com\/journals\/lancet\/article\/PIIS0140-6736(11)60982-3\/abstract?rss=yes&utm_source=feedblitz&utm_medium=FeedBlitzEmail&utm_content=196607&utm_campaign=Express_'2011-08-05+20:00:00'","http:\/\/www.thelancet.com\/journals\/lancet\/article\/PIIS0140-6736(11)60982-3\/abstract","https:\/\/images.google.be\/imgres?imgurl=https%3A%2F%2Fwww.thelancet.com%2Fcms%2Fattachment%2F2001012537%2F2003806051%2Fgr1_lrg.jpg&imgrefurl=https%3A%2F%2Fwww.thelancet.com%2Fjournals%2Flancet%2Farticle%2FPIIS0140-6736(11)60982-3%2Ffulltext&docid=MXTyVJ8rgn_fdM&tbnid=5W6t4EQ9Kq0nHM%3A&w=2565&h=2169&source=sh%2Fx%2Fim"],"pdf_url":"http:\/\/download.thelancet.com\/pdfs\/journals\/lancet\/PIIS0140673611609823.pdf","pmid":"21777972","pubdate":"2011-01-01T00:00:00+00:00","publisher":"Elsevier","publisher_subjects":[{"name":"Medical And Health Sciences","scheme":"era"}],"scopus_subjects":["Medicine","Health Sciences"],"subjects":["medicine"],"title":"Autologous non-myeloablative haemopoietic stem-cell transplantation compared with pulse cyclophosphamide once per month for systemic sclerosis (ASSIST): an open-label, randomised phase 2 trial.","type":"article","uri":"http:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0140673611609823","volume":"378","mendeley_url":"http:\/\/www.mendeley.com\/research\/autologous-nonmyeloablative-haemopoietic-stemcell-transplantation-compared-pulse-cyclophosphamide-on"},"altmetric_score":{"score":25.064,"score_history":{"1y":1,"6m":0,"3m":0,"1m":0,"1w":0,"6d":0,"5d":0,"4d":0,"3d":0,"2d":0,"1d":0,"at":25.064},"context_for_score":{"all":{"total_number_of_other_articles":8422812,"mean":7.0866213065837,"rank":360417,"this_scored_higher_than_pct":95,"this_scored_higher_than":8062448,"rank_type":"exact","sample_size":8422812,"percentile":95},"similar_age_3m":{"total_number_of_other_articles":72491,"mean":6.1837874465444,"rank":3054,"this_scored_higher_than_pct":95,"this_scored_higher_than":69437,"rank_type":"exact","sample_size":72491,"percentile":95},"this_journal":{"total_number_of_other_articles":24563,"mean":27.755578454523,"rank":4380,"this_scored_higher_than_pct":82,"this_scored_higher_than":20183,"rank_type":"exact","sample_size":24563,"percentile":82},"similar_age_this_journal_3m":{"total_number_of_other_articles":487,"mean":12.438358024691,"rank":55,"this_scored_higher_than_pct":88,"this_scored_higher_than":432,"rank_type":"exact","sample_size":487,"percentile":88}}},"demographics":{"poster_types":{"member_of_the_public":6,"researcher":3,"practitioner":3},"users":{"twitter":{"cohorts":{"Members of the public":6,"Practitioners (doctors, other healthcare professionals)":3,"Scientists":3}},"mendeley":{"by_status":{"Unspecified":3,"Professor > Associate Professor":11,"Researcher":16,"Student  > Doctoral Student":5,"Student  > Ph. D. Student":13,"Student  > Postgraduate":6,"Other":12,"Student  > Master":9,"Student  > Bachelor":2,"Lecturer":1,"Lecturer > Senior Lecturer":1,"Professor":6},"by_discipline":{"Medicine and Dentistry":58,"Social Sciences":1,"Sports and Recreations":1,"Psychology":1,"Immunology and Microbiology":6,"Economics, Econometrics and Finance":1,"Agricultural and Biological Sciences":7,"Nursing and Health Professions":1,"Unspecified":7,"Pharmacology, Toxicology and Pharmaceutical Science":2}}},"geo":{"twitter":{"US":4,"LV":1,"FR":1,"AR":1,"BE":1},"mendeley":{"JP":1,"BR":1,"IT":1,"FR":1,"PT":1}}},"posts":{"twitter":[{"url":"http:\/\/twitter.com\/#!\/cells_nnm\/status\/95285047879413760","citation_ids":[194094],"posted_on":"2011-07-25T00:11:40+00:00","author":{"name":"Alexey Bersenev","url":"http:\/\/celltrials.info","image":"https:\/\/pbs.twimg.com\/profile_images\/65057821\/avatar2_normal.jpg","description":"MD, PhD. Cell trialist.","id_on_source":"cells_nnm","tweeter_id":"14063950","geo":{"lt":41.30815,"ln":-72.92816,"country":"US"},"followers":4754},"tweet_id":"95285047879413760"},{"url":"http:\/\/twitter.com\/#!\/pvo1reuma\/status\/129016628007542784","citation_ids":[194094],"posted_on":"2011-10-26T02:08:55+00:00","author":{"id_on_source":"pvo1reuma","tweeter_id":131179322},"tweet_id":"129016628007542784"},{"url":"http:\/\/twitter.com\/#!\/pvo1reuma\/status\/129015879106174976","citation_ids":[194094],"posted_on":"2011-10-26T02:05:57+00:00","author":{"id_on_source":"pvo1reuma","tweeter_id":131179322},"tweet_id":"129015879106174976"},{"url":"http:\/\/twitter.com\/#!\/pvo1reuma\/status\/135427206901018624","citation_ids":[194094],"posted_on":"2011-11-12T18:42:16+00:00","author":{"id_on_source":"pvo1reuma","tweeter_id":163463344},"tweet_id":"135427206901018624"},{"url":"http:\/\/twitter.com\/#!\/srfcure\/status\/94086563440500736","citation_ids":[194094],"posted_on":"2011-07-21T16:49:19+00:00","author":{"name":"SRFCure","url":"http:\/\/www.srfcure.org","image":"https:\/\/pbs.twimg.com\/profile_images\/855890675501367297\/Qwdf7CHm_normal.jpg","description":"America\u2019s leading nonprofit investor in medical research to find better treatments and a cure for scleroderma.","id_on_source":"srfcure","tweeter_id":"275290061","geo":{"lt":37.77493,"ln":-122.41942,"country":"US"},"followers":2613},"tweet_id":"94086563440500736"},{"url":"http:\/\/twitter.com\/#!\/NicholasMMurphy\/status\/95027214403387392","citation_ids":[194094],"posted_on":"2011-07-24T07:07:08+00:00","author":{"name":"Nick Murphy","image":"https:\/\/pbs.twimg.com\/profile_images\/978677061\/345_n_normal.jpg","id_on_source":"nicholasmmurphy","tweeter_id":"74478819","geo":{"lt":null,"ln":null},"followers":814},"tweet_id":"95027214403387392"},{"url":"http:\/\/twitter.com\/#!\/EriksJakobsons\/status\/95231257671237632","citation_ids":[194094],"posted_on":"2011-07-24T20:37:55+00:00","author":{"name":"Eriks Jakobsons","url":"http:\/\/www.regmed.lv","image":"https:\/\/pbs.twimg.com\/profile_images\/1633291481\/4059a614-12fd-4ae4-8947-a42983762a21_normal.png","id_on_source":"eriksjakobsons","tweeter_id":"147912513","geo":{"lt":56.946,"ln":24.10589,"country":"LV"},"followers":177},"tweet_id":"95231257671237632"},{"url":"http:\/\/twitter.com\/#!\/Transplant_Doc\/status\/95348188000698368","citation_ids":[194094],"posted_on":"2011-07-25T04:22:34+00:00","author":{"name":"Muzaffar Qazilbash","url":"http:\/\/faculty.mdanderson.org\/Muzaffar_Qazilbash\/Default.asp","image":"https:\/\/pbs.twimg.com\/profile_images\/1805143659\/Profile_compressed_pic-_020412_normal.jpg","description":"Stem Cell Transplant physician and clinical researcher at MD Anderson Cancer Center; special interest in myeloma. Opinions expressed are my own","id_on_source":"transplant_doc","tweeter_id":"162587280","geo":{"lt":null,"ln":null},"followers":3421},"tweet_id":"95348188000698368"},{"url":"http:\/\/twitter.com\/#!\/Larhumato\/status\/95459404375273472","citation_ids":[194094],"posted_on":"2011-07-25T11:44:30+00:00","author":{"name":"francis berenbaum","url":"http:\/\/www.larhumato.fr","image":"https:\/\/pbs.twimg.com\/profile_images\/2211819098\/6B2A5CEF-9349-4321-B770-3882C59D6B1D_normal","description":"Soutenons la recherche sur les maladies ost\u00e9oarticulaires!Chef du service APHP St-Antoine, prof \u00e0 UPMC,Pdt d'Honneur Soc Fr Rhumatologie.Venez sur larhumato.fr!","id_on_source":"larhumato","tweeter_id":"216838030","geo":{"lt":48.85341,"ln":2.3488,"country":"FR"},"followers":2306},"tweet_id":"95459404375273472"},{"url":"http:\/\/twitter.com\/#!\/rubenroa\/status\/99634448529756160","citation_ids":[194094],"posted_on":"2011-08-06T00:14:38+00:00","author":{"name":"Ruben Roa","url":"http:\/\/medicina-general-familiar.blogspot.com","image":"https:\/\/pbs.twimg.com\/profile_images\/428849770891710464\/kgRmDYTd_normal.png","description":"Family Doctor & Epidemiologist & Health Technology Assesment","id_on_source":"rubenroa","tweeter_id":"35991485","geo":{"lt":-34.61315,"ln":-58.37723,"country":"AR"},"followers":1862},"tweet_id":"99634448529756160"},{"url":"http:\/\/twitter.com\/#!\/srviswanathan\/status\/94111279156961280","citation_ids":[194094],"posted_on":"2011-07-21T18:27:32+00:00","author":{"name":"Srinivas Viswanathan","image":"https:\/\/abs.twimg.com\/sticky\/default_profile_images\/default_profile_normal.png","description":"Heme\/Onc fellow and aspiring physician-scientist with interests in stem cells, oncology, amd RNA","id_on_source":"srviswanathan","tweeter_id":"230237317","geo":{"lt":42.35843,"ln":-71.05977,"country":"US"},"followers":110},"tweet_id":"94111279156961280"},{"url":"http:\/\/twitter.com\/#!\/cells_nnm\/status\/95208170674327552","citation_ids":[194094],"posted_on":"2011-07-24T19:06:11+00:00","author":{"name":"Alexey Bersenev","url":"http:\/\/celltrials.info","image":"https:\/\/pbs.twimg.com\/profile_images\/65057821\/avatar2_normal.jpg","description":"MD, PhD. Cell trialist.","id_on_source":"cells_nnm","tweeter_id":"14063950","geo":{"lt":41.30815,"ln":-72.92816,"country":"US"},"followers":4754},"tweet_id":"95208170674327552"},{"url":"http:\/\/twitter.com\/#!\/CellTrials\/status\/95207951903637504","citation_ids":[194094],"posted_on":"2011-07-24T19:05:19+00:00","author":{"name":"Cell Therapy Trials","url":"http:\/\/celltrials.info","image":"http:\/\/abs.twimg.com\/sticky\/default_profile_images\/default_profile_5_normal.png","description":"We track clinical trials and cases in cell therapy and regenerative medicine. The person behind a project @cells_nnm","id_on_source":"celltrials","tweeter_id":"283066411","geo":{"lt":"39.952335","ln":"-75.163789","country":"US"},"followers":695},"tweet_id":"95207951903637504"},{"url":"http:\/\/twitter.com\/cells_nnm\/statuses\/741394288475529216","license":"gnip","citation_ids":[3022321,194094],"posted_on":"2016-06-10T22:19:07+00:00","author":{"name":"Alexey Bersenev","url":"http:\/\/celltrials.info","image":"https:\/\/pbs.twimg.com\/profile_images\/65057821\/avatar2_normal.jpg","description":"MD, PhD. Cell trialist.","id_on_source":"cells_nnm","tweeter_id":"14063950","geo":{"lt":41.30815,"ln":-72.92816,"country":"US"},"followers":4754},"tweet_id":"741394288475529216"},{"url":"http:\/\/twitter.com\/sanguinebiomab\/statuses\/846276706432434176","license":"gnip","citation_ids":[194094],"posted_on":"2017-03-27T08:24:24+00:00","author":{"name":"Ann Van de Velde","url":"http:\/\/biomedicalart.blogspot.be","image":"https:\/\/pbs.twimg.com\/profile_images\/256869374\/n1251402415_287190_531_normal.jpg","description":"Haematologist Antwerp University Hospital; Founder and Board Member BIOMAB - Biological and Medical Art in Belgium","id_on_source":"sanguinebiomab","tweeter_id":"46047864","geo":{"lt":51.13128,"ln":4.57042,"country":"BE"},"followers":213},"tweet_id":"846276706432434176"}],"facebook":[{"title":"Autologous non-myeloablative haemopoietic stem-cell transplantation compared with pulse cyclophospha","url":"https:\/\/www.facebook.com\/permalink.php?story_fbid=221720371205962&id=148109355242779","citation_ids":[194094],"posted_on":"2011-07-21T20:36:35+00:00","summary":"Big news coming in scleroderma research, with this article slated to be published in The Lancet in the next couple of weeks!  Dr. Burt was one of two researchers who presented at the Scleroderma National Convention on this promising treatment.  It is inten","author":{"name":"Scleroderma Foundation, Greater San Diego Chapter","url":"https:\/\/www.facebook.com\/148109355242779","facebook_wall_name":false,"image":"https:\/\/graph.facebook.com\/148109355242779\/picture","id_on_source":"148109355242779"}},{"title":"Autologous non-myeloablative haemopoietic stem-cell transplantation compared with pulse cyclophospha","url":"https:\/\/www.facebook.com\/permalink.php?story_fbid=132831946803546&id=147792885286506","citation_ids":[194094],"posted_on":"2011-07-26T00:26:07+00:00","summary":"http:\/\/www.thelancet.com\/journals\/lancet\/article\/PIIS0140-6736(11)60982-3\/abstract","author":{"name":"Colegio Mexicano de Reumatolog\u00eda A.C.","url":"https:\/\/www.facebook.com\/147792885286506","facebook_wall_name":"Colegio Mexicano de Reumatolog\u00eda A.C.","image":"https:\/\/graph.facebook.com\/147792885286506\/picture","id_on_source":"147792885286506"}}],"blogs":[{"title":"Should we all be guinea pigs?","url":"http:\/\/www.smartplanet.com\/blog\/savvy-scientist\/should-we-all-be-guinea-pigs\/520","citation_ids":[1234457,194094,170732],"posted_on":"2012-07-11T09:23:00+00:00","summary":"Medical tourism and the rise of electronic health records could make all of us experimental subjects. But not all experiments are created equal.","author":{"name":"The Savvy Scientist | SmartPlanet","url":"http:\/\/www.smartplanet.com\/blog\/savvy-scientist","description":"The Savvy Scientist dives into the ethics, issues and innovations brewing in the world's most advanced research institutions."}}],"news":[{"title":"Scleroderma patients seek experimental U.S. stem cell therapy","url":"http:\/\/www.ctvnews.ca\/health\/scleroderma-patients-seek-experimental-u-s-stem-cell-therapy-1.2071491","license":"public","citation_ids":[194094],"posted_on":"2014-10-26T02:15:00+00:00","summary":"There is no cure for the scleroderma, an incurable autoimmune disorder which causes the body to produce too much collagen, but some patients in Canada are now seeking a costly and experimental stem cell therapy in the U.S.","author":{"name":"CTV News","url":"http:\/\/www.ctvnews.ca\/","image":"https:\/\/s3.amazonaws.com\/weyland.altmetric.com\/news_sources\/logos\/000\/000\/019\/normal\/ctv_news.png?1369846909"}}]}}